替奈普酶(Tenecteplase) - 药物靶点：PLG_在研适应症：急性缺血性卒中，ST段抬高心肌梗死，急性心肌梗塞_专利_临床

概要

基本信息

药物类型

酶

别名

Metalyse、Tenecteplase (USAN/INN)、TNK

+ [5]

靶点

PLG

作用机制

PLG刺激剂(纤溶酶原刺激剂)

治疗领域

心血管疾病神经系统疾病其他疾病

在研适应症

急性缺血性卒中ST段抬高心肌梗死急性心肌梗塞+ [4]

非在研适应症

导管功能障碍新型冠状病毒感染心脏停搏+ [6]

原研机构

Genentech, Inc.

在研机构

Boehringer Ingelheim Pharma GmbH & Co., KGBoehringer Ingelheim International GmbH

Genentech, Inc.

+ [1]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2000-06-02),

急性心肌梗塞

最高研发阶段(中国)申请上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 431641667

来源: *****

关联

90

项与替奈普酶相关的临床试验

NCT06801054

/ Not yet recruiting临床1期IIT

SAFETY OF A SECOND DOSE OF TENECTEPLASE IN SELECTED ACUTE ISCHEMIC STROKE PATIENTS NOT RESPONDING TO THE FIRST DOSE

In this pilot safety study, we will give a second dose of Intravenous Tenecteplase (IV TNK) to patients receiving the initial TNK dose within 3 hrs of last known normal (LKN), have a baseline National Institutes of Health Stroke Scale (NIHSS) > 6, and who do not clinically improve within 45 minutes of the first dose, or who improve but then deteriorate, and can still be treated within 4.5 hours from LKN. Patients will require a second computed tomography (CT) scan to rule out any bleeding, and meet the usual inclusion and exclusion criteria for TNK treatment, before the second dose which must be given within 4.5 hrs of LKN. Both TNK doses will be 0.25 mg/kg. The initial TNK dose may be given on the Mobile Stroke Unit (MSU) or Emergency Department (ED), and the second dose in the ED. Informed consent will be obtained before the second dose is given.
The primary outcome will be symptomatic intracranial hemorrhage (sICH) (SITS-MOST criteria) or serious systemic bleeding within 36 hours. Secondary outcomes will be any intracranial hemorrhage, any bleeding, discharge NIHSS and modified Rankin Score (mRS), and mRS at 90 days (sliding dichotomy).
20 patients will be enrolled. Enrollment will be stopped if more than 3 sICH occur (> 80% confidence that sICH rate is > 5%. If successful, this study will be followed by a larger phase 2b controlled safety confirmation and pilot efficacy study,

开始日期2025-03-01

申办/合作机构

Memorial Hermann Health System

[+1]

NCT06781385

/ Not yet recruiting临床2期IIT

Intra-Arterial Tenecteplase Following Endovascular Thrombectomy for Large Vessel Occlusion Stroke

The purpose of this study is to determine the safety and feasibility of using intra-arterial Tenecteplase in patients undergoing blood clot extraction for treatment of acute ischemic (non-bleeding) stroke. Tenecteplase is a drug that is currently FDA-approved to treat a heart attack but not currently approved for stroke treatment.

开始日期2025-03-01

申办/合作机构

Wake Forest School of Medicine

[+1]

IRCT20241023063472N1

/ Suspended临床3期IIT

Comparison of thrombolytic therapy with Alteplase and Tenecteplase for in patients with acute ischemic stroke in a clinical trial phase 3.

开始日期2025-02-19

申办/合作机构-

100 项与替奈普酶相关的临床结果

登录后查看更多信息

100 项与替奈普酶相关的转化医学

登录后查看更多信息

100 项与替奈普酶相关的专利（医药）

登录后查看更多信息

938

项与替奈普酶相关的文献（医药）

2025-12-31·Hospital practice (1995)

Assessment of transition from use of alteplase to tenecteplase in the treatment of acute ischemic stroke in a large system of community hospitals

Article

作者: Hasse, Adam ; Poland, Russell E. ; Korwek, Kimberly ; Guy, Jeffrey

OBJECTIVE:

Pharmacologic thrombolytic treatment for acute ischemic stroke has primarily been managed by intravenous alteplase. Tenecteplase is a variant that has been shown to be non-inferior to alteplase in clinical trials. In this study, we present a real-world assessment of patient outcomes with the facility-wide transition to the use of tenecteplase versus altepase for acute ischemic stroke in a large system of community hospitals in the United States.

METHODS:

This retrospective analysis assessed adult patients who received either alteplase or tenecteplase between 1 April 2020 and 31 March 2023. Propensity matching was used to estimate the covariate-adjusted association with outcomes of discharge expired/hospice, intracranial hemorrhage and readmission to a facility in the same healthcare system within 30, 60, or 90 days.

RESULTS:

Among 12,766 patients, gross mortality was 7.6% (n = 285) with tenecteplase and 8.2% (n = 739) with alteplase (p = 0.314); intracranial hemorrhage was 2.4% with either. The propensity match analysis found that the relative risk of mortality/hospice for patients given tenecteplase versus alteplase was 0.993 (95% CI: 0.848-1.162, p = 1.000). When limited to five facilities with the highest volume of thrombolytic use, there were no significant differences in outcomes. While the time from emergency department arrival to thrombolytic administration (door-to-needle) was shorter among patients receiving tenecteplase, there was no significant difference in the odds of mortality based on door-to-needle time.

CONCLUSION:

In alignment with previous studies, these findings demonstrate the lack of potential harm with a transition from alteplase to tenecteplase in clinical practice for acute ischemic stroke patients treated in community hospitals.

2025-04-01·Journal of Stroke & Cerebrovascular Diseases

Corrigendum to “Door-to-Needle Time Trends After Transition to Tenecteplase: A Multicenter Texas Stroke Registry” [Journal of Stroke and Cerebrovascular Diseases 33 (2024) 107774]

作者: Gebreyohanns, Mehari ; Anderson, Jane A ; Rodriguez, Nathaniel ; Brown, Gretchel Gealogo ; Olson, DaiWai M ; Savitz, Sean I ; Bandela, Sujani ; Prasad, Sidarrth ; Stone, Suzanne ; Goldberg, Mark P ; Ifejika, Nneka L ; Birnbaum, Lee A ; Kwon, Yoon ; Jones, Erica M ; Cruz-Flores, Salvador ; Warach, Steven J

2025-03-01·MEDICAL CLINICS OF NORTH AMERICA

Therapeutic Options for Disabling Acute Ischemic Stroke

Review

作者: Moreno-Gomez, Veronica ; Wold, Jana J

Ischemic stroke affects up to 3% of the US population and is the leading cause of disability nationwide. This article outlines the evidence to support the use of intravenous thrombolytic, including tenecteplase, in the setting of acute ischemic stroke, along with thrombectomy for up to 24 hours, even in those patients with a large ischemic core and in those with an acute basilar artery occlusion. A clinical case of a patient with large ischemic core who received thrombectomy is included, along with images.

60

项与替奈普酶相关的新闻（医药）

2025-03-05

·求实药社

近30年来首款中风药物！罗氏创新疗法获FDA批准

来源：药渡罗氏（Roche）旗下基因泰克（Genentech）昨日宣布，美国FDA已批准血栓溶解剂TNKase（tenecteplase）上市，用于治疗成人急性缺血性中风（AIS）。新闻稿指出，TNKase是FDA近30年来批准的首款中风药物。TNKase通过一次五秒的静脉推注给药，与同为罗氏开发的标准治疗Activase（先进行静脉推注，再进行60分钟输注）相比，这种给药方式更快速和便捷。此次批准基于一项大型多中心非劣效性研究，这项临床试验比较了TNKase和Activase在治疗表现出致残性神经缺陷的急性缺血性中风患者时的表现。研究结果显示，在急性缺血性中风患者中，TNKase在安全性和疗效方面与Activase相当。在急性缺血性中风过程中，大脑损伤迅速发生和加剧，每一刻没有及时干预都会导致不可逆的神经组织丧失，因此立即接受治疗至关重要。 TNKase是一种组织纤溶酶原激活剂，具有溶解血栓的作用。TNKase以一次五秒的静脉推注给药，启动一种能够分解血栓成分纤维蛋白的生化反应。其最常见的不良反应为出血和过敏反应。免责声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担, 关于对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部。联系我们 SIT 2025 展位火热预定中！扫码立即咨询电话：13816031174 （同微信）赞助形式包括但不仅限于演讲席位、会场展位、会刊彩页、晚宴赞助、会议用品宣传等。点击此处“阅读全文”咨询更多精彩！

上市批准突破性疗法

2025-03-05

·SYNAPSE

2025年3月5日全球新药进展早知道

1. 抗CD19单抗「伊奈利珠单抗」新适应症申报上市 3月4日，CDE官网公示，由Horizon Therapeutics、阿斯利康和翰森制药共同申报伊奈利珠单抗注射液一项新适应症上市申请获得受理。伊奈利珠单抗是一款抗CD19单抗，该产品于今年2月刚刚被CDE正式纳入优先审评，用于免疫球蛋白G4相关疾病（IgG4-RD）成人患者的治疗。由此推测，这可能就是本次该产品申报上市的适应症。2019年，翰森制药与Viela Bio订立许可协议，获得于中国内地、香港和澳门地区开发及商业化该产品的独家许可（Viela Bio于2021年被Horizon Therapeutics收购，后者于2023年被安进收购）。伊奈利珠单抗此前已经在美国和中国获批上市，用于治疗抗水通道蛋白4（AQP4）抗体阳性的视神经脊髓炎谱系障碍（NMOSD）成人患者。 2. 百济神州「替雷利珠单抗」在美获批新适应症，一线食管鳞癌 3月4日，百济神州宣布，美国FDA已批准百泽安®（替雷利珠单抗）联合含铂化疗用于肿瘤表达PD-L1（≥1）的不可切除或转移性食管鳞状细胞癌（ESCC）成人患者一线治疗。本次替雷利珠单抗获批新适应症是基于百济神州RATIONALE-306试验的结果。替雷利珠单抗是一款人源化IgG4抗PD-1单克隆抗体，此前已在美国获批作为单药用于治疗既往接受过系统化疗（不含PD-1/PD-L1抑制剂）后不可切除或转移性ESCC的成人患者，以及联合化疗用于胃和胃食管结合部（G/GEJ）癌成人患者的一线治疗。 3. FDA批准罗氏中风药物替奈普酶 3 月 3 日，罗氏旗下公司基因泰克宣布，美国 FDA 已批准替奈普酶（商品名：TNKase）用于治疗成人急性缺血性中风（AIS）。新闻稿指出，这是近 30 年来 FDA 批准的首个中风药物。替奈普酶并不是一款新疗法，此前该产品早已获得 FDA 批准用于治疗成人急性 ST 段抬高型心肌梗死。替奈普酶是一款组织纤溶酶原激活剂、凝块溶解剂和血栓溶解剂，以单次静脉 (IV) 推注的方式给药，给药时间为五秒钟。与标准治疗药物阿替普酶（静脉推注，输液 60 分钟）相比，替奈普酶给药速度更快、更简单。基因泰克计划在未来几个月推出一种新的 25 mg 小瓶配置，以支持替奈普酶用于 AIS 的批准。 4. 默沙东抗病毒新药新剂型拟纳入优先审评 3月4日，CDE官网公示，默沙东（MSD）申报的来特莫韦微片拟纳入优先审评，用于接受异基因造血干细胞移植（HSCT）的巨细胞病毒（CMV）血清学阳性的成人和6个月及以上且体重≥6kg的儿童受者[R+]预防巨细胞病毒感染和巨细胞病毒病。来特莫韦是一种新型非核苷类巨细胞病毒（CMV）抑制剂，该产品的片剂和注射剂剂型此前已经在中国获批上市。根据CDE公示，来特莫韦微片属于儿童新品种。本次拟纳入优先审评的是来特莫韦微片剂型。公开资料显示，微片是指直径不超过4mm的微型片剂，是世界卫生组织和中国儿童用药开发指导原则中推荐的适合儿童的小剂量制剂改进方案。 5. 阿斯利康/安进Tezspire 3期临床研究结果登《新英格兰医学杂志》 3月3日，阿斯利康（AstraZeneca）和安进（Amgen）日前宣布，其联合开发的Tezspire（tezepelumab）在3期临床试验WAYPOINT中获得的完整结果，已在《新英格兰医学杂志》上发表。试验达到了共同主要终点，在慢性鼻窦炎伴鼻息肉（CRSwNP）患者中，使用Tezspire治疗在52周时与安慰剂相比，显著降低了鼻息肉评分（NPS）和及参与者自评的鼻塞评分（NCS）。NPS降低幅度为-2.065（95% CI：-2.389，-1.742；p<0.0001），NCS降低幅度为-1.028（95% CI：-1.201，-0.855；p<0.0001）。值得一提的是，患者在接受治疗第2周就观察到了NCS的改善，并持续至第52周。 6. 诺华新一代核药启动III期临床，直接冲击一线治疗 3月3日，全球临床试验收录网站显示，诺华启动了新一代放射配体疗法（RLT）AAA817（ [225Ac]Ac-PSMA-617）的III期临床试验（AcTFirst）。AAA817是诺华收购Endocyte后获得的一款α粒子核药。该研究是一项多中心、随机、开放标签、阳性药物对照临床试验（n=486），旨在评估AAA817联合雄激素受体信号通路抑制剂（ARPI）对比研究者选择的标准治疗（SoC）治疗未接受过含紫杉醇化疗方案和RLT治疗的PSMA阳性转移性去势抵抗性前列腺癌（mCRPC）患者的有效性和安全性。研究的主要终点是影像学无进展生存期（rPFS）。 7. 翰森制药B7-H4 ADC启动III期临床 3月3日，药物临床试验登记与信息公示平台显示，翰森制药启动了HS-20089（GSK5733584）的首个III期临床试验。这是首个进入III期临床阶段的B7-H4 ADC药物。该研究是一项多中心、随机、开放、阳性药物对照临床试验（n=468），旨在评估HS-20089对比研究者选择的化疗（托泊替康、紫杉醇、多柔比星脂质体）治疗铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌患者的有效性和安全性。研究的主要终点为独立影像评审委员会（BICR）根据RECIST v1.1标准评估的无进展生存期（PFS）。 1. 1.87亿美元！下一代ADC新锐完成A轮融资 3月3日，Callio Therapeutics宣布完成1.87亿美元A轮融资。本轮融资由Frazier Life Sciences领投，Jeito Capital、Novo Holdings A/S等跟投。这家新成立的公司总部位于西雅图和新加坡，将利用A轮融资的收益，实现其靶向HER2的双载荷ADC，以及第二个未披露的ADC项目的临床概念验证。Callio Therapeutics正在开发下一代多载荷ADC，这种ADC采用差异化的有效载荷和接头技术，能够将多载荷靶向递送至肿瘤细胞，从而最大限度地提高治疗效果。Callio Therapeutics的首个项目是靶向HER2的双有效载荷ADC。内容来源于网络，如有侵权，请联系删除。

优先审批临床研究融资

2025-03-05

·PMLiVE

Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke

Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in acute ischaemic stroke (AIS). The drug, which has been authorised for use in adults, is now the first stroke medicine to be approved by the regulator in almost three decades. Stroke is the fifth leading cause of death and the leading cause of long-term disability in the US, affecting more than 795,000 people every year. An AIS occurs when the blood supply to part of the brain is blocked or reduced, preventing brain tissue from receiving oxygen and nutrients. TNKase is a tissue plasminogen activator, clot-dissolving, thrombolytic medicine that starts a biochemical reaction that can break down fibrin, a component of blood clots. Until now, the only FDA-approved medicine for AIS was Roche/Genentech’s Activase (alteplase), which is administered as an intravenous (IV) bolus followed by a 60-minute infusion. TNKase, delivered as a single five-second IV bolus, offers a faster and simpler administration compared to Activase. The drug is also already approved in the US to treat acute ST-elevation myocardial infarction in adults. The FDA’s latest decision was supported by results from a large multi-centre non-inferiority study demonstrating that TNKase is comparable to Activase in AIS patients in terms of safety and efficacy. Levi Garraway, Genentech’s chief medical officer and head of global product development, said: “[This] approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients. “TNKase provides a faster and simpler administration, which can be critical for anyone who is dealing with an acute stroke.” The authorisation comes less than a month after the FDA approved a tablet formulation of Roche’s spinal muscular atrophy treatment Evrysdi (risdiplam). Evrysdi was originally authorised by the US regulator in 2020 to treat the progressive neuromuscular disease in patients aged two months and older, before being granted expanded approval in 2022 for infants aged under two months. It is hoped that the tablet formulation, which can either be swallowed whole or dispersed in water and stored at room temperature, will provide more freedom and independence over the original oral solution.

上市批准

100 项与替奈普酶相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06070	替奈普酶	B01AD11	DB00031

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
急性缺血性卒中	美国	Genentech, Inc.	2025-02-28
ST段抬高心肌梗死	美国	Genentech, Inc.	2025-02-28
急性心肌梗塞	美国	Genentech, Inc.	2000-06-02

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
闭塞	临床3期	巴西	Boehringer Ingelheim GmbH	2022-01-20
脑卒中	临床3期	美国	Genentech, Inc.	2019-03-02
脑卒中	临床3期	加拿大	Genentech, Inc.	2019-03-02
血栓形成	临床3期	美国	Genentech, Inc.	2019-03-02
血栓形成	临床3期	加拿大	Genentech, Inc.	2019-03-02
胸腔积液	临床3期	美国	Genentech, Inc.	2008-01-01
肺栓塞	临床3期	奥地利	Boehringer Ingelheim GmbH	2007-11-16
肺栓塞	临床3期	比利时	Boehringer Ingelheim GmbH	2007-11-16
肺栓塞	临床3期	法国	Boehringer Ingelheim GmbH	2007-11-16
肺栓塞	临床3期	德国	Boehringer Ingelheim GmbH	2007-11-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03889249 (FDA_CDER) 人工标引	临床3期	急性缺血性卒中	1,147	TNKase	選憲醖鹹憲鏇醖淵顧獵(憲膚糧膚夢壓選觸積艱) = 網蓋醖憲糧鹹繭鑰憲鑰壓簾憲憲遞膚簾壓鹹獵 (夢獵遞簾遞構觸鹹顧繭 )	积极	2025-02-28
				Activase	選憲醖鹹憲鏇醖淵顧獵(憲膚糧膚夢壓選觸積艱) = 鹽獵獵憲網淵鹽糧壓構壓簾憲憲遞膚簾壓鹹獵 (夢獵遞簾遞構觸鹹顧繭 )
NCT04915729 (ORIGINAL, CTgov)	临床3期	急性缺血性卒中	1,489	tenecteplase (Tenecteplase Treatment Group)	獵壓鬱簾夢鑰獵範顧繭(憲鹹憲構膚壓醖蓋顧獵) = 夢積製築鬱觸淵鹹醖製獵艱顧繭壓醖淵選壓餘 (齋壓簾獵襯淵蓋鹽夢衊, 選築艱網鏇蓋醖艱齋顧 ~ 窪積壓範艱齋選齋壓簾) 更多	-	2024-12-10
				alteplase (Alteplase Active Control Group)	獵壓鬱簾夢鑰獵範顧繭(憲鹹憲構膚壓醖蓋顧獵) = 壓衊繭顧壓齋遞夢鑰衊獵艱顧繭壓醖淵選壓餘 (齋壓簾獵襯淵蓋鹽夢衊, 窪衊壓鹹窪壓廠積膚製 ~ 簾餘襯積鏇構醖糧範襯) 更多
NCT02814409 (ATTEST-2, Pubmed) 人工标引	临床3期	脑卒中	1,777	Tenecteplase 0·25 mg/kg	構繭顧鬱積構餘觸憲鹹(觸膚網顧構淵獵簾簾糧) = 網壓膚醖鑰醖夢齋鬱壓製襯繭壓憲窪鏇壓簾齋 (糧淵構窪構鹽選齋鏇壓 ) 更多	非劣	2024-11-01
				Alteplase 0·9 mg/kg	構繭顧鬱積構餘觸憲鹹(觸膚網顧構淵獵簾簾糧) = 廠構糧鏇襯選鏇構顧夢製襯繭壓憲窪鏇壓簾齋 (糧淵構窪構鹽選齋鏇壓 ) 更多
NCT02777580 (STREAM-2, CTgov)	临床4期	心肌梗塞	609	Coronary angiography+clopidogrel+Tenecteplase (Pharmaco-invasive Strategy)	齋構蓋膚廠艱構觸襯壓(築構膚築選廠願範醖選) = 憲壓艱獵構鬱糧選製觸廠範顧築壓鏇積製鏇襯 (鬱顧範鑰鹽餘鏇顧醖獵, 餘窪鑰壓顧窪繭鏇觸遞 ~ 襯餘選蓋衊襯顧顧鹽構) 更多	-	2024-10-04
				Primary PCI (Standard Primary PCI)	齋構蓋膚廠艱構觸襯壓(築構膚築選廠願範醖選) = 遞衊憲繭鬱夢糧壓鬱鹽廠範顧築壓鏇積製鏇襯 (鬱顧範鑰鹽餘鏇顧醖獵, 艱淵顧窪網顧餘觸簾鬱 ~ 簾遞構鑰製繭鬱範網糧) 更多
NCT03785678 (TIMELESS, CTgov)	临床3期	血栓形成 \| 脑卒中	458	Tenecteplase (Tenecteplase)	網淵齋獵衊願觸艱衊餘(選襯簾鏇製製鏇餘願鏇) = 範醖憲醖築夢選願觸觸願鑰鹽糧築蓋選齋醖積 (獵夢艱築糧觸襯鬱憲鏇, 築廠夢窪艱鏇繭夢鹹鏇 ~ 鑰獵選願鹹齋獵餘鏇鹽) 更多	-	2024-05-22
				Placebo (Placebo)	網淵齋獵衊願觸艱衊餘(選襯簾鏇製製鏇餘願鏇) = 膚製鬱積壓繭衊製構壓願鑰鹽糧築蓋選齋醖積 (獵夢艱築糧觸襯鬱憲鏇, 鏇顧築願簾製膚顧壓鹽 ~ 鑰蓋網餘製鑰廠鬱壓衊) 更多
P2-5.005 (AAN2024)	N/A	急性缺血性卒中	500	Tenecteplase (TNK)	壓醖餘築蓋廠鑰襯衊鹽(壓衊網齋窪淵築鬱製餘) = 餘餘獵膚鏇鬱糧網醖齋鬱齋夢鑰鑰鏇鏇壓製艱 (遞願鹹鏇淵淵網顧夢鹽, 0.57–1.74)	积极	2024-04-09
P7-5.021 (AAN2024)	N/A	急性缺血性卒中	1	Tenecteplase	選艱製齋衊簾築蓋淵繭(齋糧鏇製構鏇襯網衊選) = 窪鬱餘餘糧壓構顧窪鹽齋選鏇觸選構鹽網鬱範 (壓鏇顧鹽簾觸壓糧憲積 )	积极	2024-04-09
AAN2024	N/A	急性缺血性卒中	-	Tenecteplase	獵醖憲夢選鬱齋製鏇鹹(構網鹹醖襯鹽襯膚憲鑰) = 遞積繭夢積夢醖構構願膚網製壓壓夢遞膚膚獵 (簾艱獵鹹鏇築鹽鑰鹹鏇 )	-	2024-04-09
AAN2024	N/A	糖尿病	-	Alteplase (ALT)	廠遞壓構憲網鹹鹹鹽積(繭鏇選鏇蓋鏇簾鏇築構) = 窪築顧鬱願鹹壓積繭願顧艱繭構蓋齋願網鑰憲 (壓網簾獵壓鹽艱艱醖鏇, 3.1% ~ 43.2%) 更多	-	2024-04-09
				Tenecteplase (TNK)	廠遞壓構憲網鹹鹹鹽積(繭鏇選鏇蓋鏇簾鏇築構) = 憲齋繭蓋範網壓獵鏇遞顧艱繭構蓋齋願網鑰憲 (壓網簾獵壓鹽艱艱醖鏇, 0.2% ~ 16.9%) 更多
ISC2024 人工标引	N/A	急性缺血性卒中	500	Tenecteplase	觸構鏇壓夢範鏇範淵製(網獵淵憲願鏇遞淵齋簾) = 齋膚窪糧衊廠襯膚糧鑰積願衊遞糧襯襯淵選遞 (艱網觸鑰淵選鏇壓齋艱 )	积极	2024-02-01
				Alteplase	-